SCHEMBL4336129

SCHEMBL4336129

Nc1cc(-c2ccc(C(=O)O)cc2)ccc1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.66
LMNA P02545 2/20 0.66
HSD17B10 Q99714 2/20 0.66
GAA P10253 2/20 0.66
MAPT P10636 2/20 0.66
KMT2A Q03164 2/20 0.66
MEN1 O00255 1/20 0.66
USP2 O75604 1/20 0.66
ALDH1A1 P00352 1/20 0.66
HSP90AA1 P07900 1/20 0.66
HPGD P15428 1/20 0.66
ALOX15 P16050 1/20 0.66
ALOX12 P18054 1/20 0.66
HTT P42858 1/20 0.66
ERN1 O75460 2/20 0.59
PPM1B O75688 1/20 0.59
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA9 Q16790 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10774366 0.98 KDM4E (0.63) KDM4ELMNAHSD17B10GAAMAPT
SCHEMBL2404415 0.85 HSD17B10 (0.65) KDM4ELMNAHSD17B10KMT2AALOX15
SCHEMBL28566580 0.84 KMT2A (0.58) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL29904702 0.84 KMT2A (0.58) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL9796871 0.84 KMT2A (0.58) KDM4ELMNAHSD17B10KMT2AMEN1
SCHEMBL4349925 0.84 LMNA (0.65) KDM4ELMNAHSD17B10GAAMAPT
SCHEMBL79989 0.84 KDM4E (0.64) KDM4ELMNAHSD17B10GAAMAPT
SCHEMBL29476052 0.84 KDM4E (0.64) KDM4ELMNAHSD17B10GAAMAPT
Hydrochloric Acid SCHEMBL17559530 0.83 HSD17B10 (0.63) KDM4ELMNAHSD17B10KMT2AALOX15
Sulfur Dioxide SCHEMBL28576865 0.83 KMT2A (0.52) KDM4ELMNAHSD17B10GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-0291778-B1 Process for the preparation of high temperature-resistant dielectrics SIEMENS AG (DE) 1994-03-16 EP disclosed
EP-0231373-B1 A PROCESS FOR THE PRODUCTION OF A LIQUID CRYSTALLINE EXTENDED CHAIN POLYMER COMPOSITION THE DOW CHEMICAL COMPANY (US) 1991-01-30 EP disclosed
US-4965134-A Method for manufacturing highly heat-resistant dielectrics SIEMENS AKTIENGESELLSCHAFT (DE) 1990-10-23 US disclosed
US-4847350-A Preparation of aromatic heterocyclic polymers THE DOW CHEMICAL COMPANY (US) 1989-07-11 US disclosed
EP-0231373-A1 A PROCESS FOR THE PRODUCTION OF A LIQUID CRYSTALLINE EXTENDED CHAIN POLYMER COMPOSITION. COMMTECH INT (US) 1987-08-12 EP disclosed
WO-1987000844-A1 A PROCESS FOR THE PRODUCTION OF A LIQUID CRYSTALLINE EXTENDED CHAIN POLYMER COMPOSITION COMMTECH INTERNATIONAL (US) 1987-02-12 WO disclosed
WO-1985004178-A1 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS SRI INTERNATIONAL (US) 1985-09-26 WO disclosed
EP-0119271-A4 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS. STANFORD RES INST INT (US) 1985-07-01 EP disclosed
EP-0119271-A1 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS. STANFORD RES INST INT (US) 1984-09-26 EP disclosed
EP-0119192-A1 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS SRI INTERNATIONAL (US) 1984-09-26 EP disclosed
EP-0119202-A1 LIQUID CRYSTALLINE POLY(2,6-BENZOTHIAZOLE) COMPOSITIONS, PROCESS AND PRODUCTS SRI INTERNATIONAL (US) 1984-09-26 EP disclosed
WO-1984001160-A1 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS STANFORD RES INST INT (US) 1984-03-29 WO disclosed
WO-1984001161-A1 LIQUID CRYSTALLINE POLY(2,6-BENZOTHIAZOLE) COMPOSITIONS, PROCESS AND PRODUCTS STANFORD RES INST INT (US) 1984-03-29 WO disclosed
WO-1984001162-A1 LIQUID CRYSTALLINE POLYMER COMPOSITIONS, PROCESS, AND PRODUCTS STANFORD RES INST INT (US) 1984-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KDM4E 3202/4885LMNA 4580/4885HSD17B10 2374/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK KDM4E 3202/4885LMNA 4580/4885HSD17B10 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.